The introduction of novel agents such as Bruton’s tyrosine kinase inhibitors, proteasome inhibitors, immunomodulatory drugs, and chimeric antigen receptor T-cell therapy has revolutionized the treatment landscape for various lymphoma subtypes. Here, BTK is linked to lymphoma.